By Matt Sussman
Determining fair and reasonable drug prices in the U.S. has long been a source of debate. Unlike countries such as Australia and Canada, which have established health technology assessment (HTA) organizations, the U.S. has long lacked consistent, independent economic analysis to assess the value of new drugs.
While four U.S. value assessment frameworks have been created by clinical societies, including the American Heart Association, to inform physician and patient decisions, these frameworks tend to focus on one specific therapeutic area in support of treatment decision-making. As a result, there’s no predetermined way to evaluate the clinical and economic value for new medications that come to market.